Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec 16;385(25):2397-2399.
doi: 10.1056/NEJMc2114706. Epub 2021 Nov 3.

Neutralization of the SARS-CoV-2 Mu Variant by Convalescent and Vaccine Serum

Keiya Uriu  1 , Izumi Kimura  1 , Kotaro Shirakawa  2 , Akifumi Takaori-Kondo  2 , Taka-Aki Nakada  3 , Atsushi Kaneda  3 , So Nakagawa  4 , Kei Sato  5 ; Genotype to Phenotype Japan (G2P-Japan) Consortium
Affiliations

Neutralization of the SARS-CoV-2 Mu Variant by Convalescent and Vaccine Serum

Keiya Uriu et al. N Engl J Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1. SARS-CoV-2 in Colombia and Characterization of the Mu Variant.
Panel A shows new cases of coronavirus disease 2019 (Covid-19) from January through August 2021 in Colombia. The mu variant was first isolated on January 11, 2021, in Colombia (Global Influenza Surveillance and Response System accession number, EPI_ISL_1220045). The black line reflects the number of new weekly cases, and the colored bars indicate the percentage of each variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among the cases. The raw data are summarized in Table S2 in the Supplementary Appendix. Panels B and C show the results of virus neutralization assays. Neutralization assays were performed with the use of pseudoviruses harboring the SARS-CoV-2 spike proteins of the alpha, beta, gamma, delta, epsilon, lambda, or mu variants or the B.1 lineage virus, which harbors the D614G mutation (parental virus). Serum samples were obtained from 13 persons who had recovered from Covid-19 (Panel B) and from 14 persons who had received the BNT162b2 vaccine (Panel C). The assay of each serum sample was performed in triplicate to determine the 50% neutralization titer. Each data point represents an individual sample (circles) and indicates the 50% neutralization titer obtained with each sample against the indicated pseudovirus. The heights of the bars and the numbers over the bars indicate the geometric mean titers, and the 𝙸 bars indicate 95% confidence intervals. The numbers in parentheses indicate the average difference in neutralization resistance of the indicated variants as compared with that of the parental virus. The horizontal dashed lines indicate the limit of detection. The raw data and information regarding the convalescent donors (sex, age, severity of disease, and dates of testing and sampling) and vaccinated donors (sex, age, and dates of second vaccination and sampling) of serum samples are summarized in Tables S6 and S7 in the Supplementary Appendix.
See this image and copyright information in PMC

References

    1. World Health Organization. Tracking SARS-CoV-2 variants. 2021. (https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/).
    1. Harvey WT, Carabelli AM, Jackson B, et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol 2021;19:409-424. - PMC - PubMed
    1. Collier DA, De Marco A, Ferreira IATM, et al. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. Nature 2021;593:136-141. - PMC - PubMed
    1. Wang P, Nair MS, Liu L, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature 2021;593:130-135. - PubMed
    1. Hacisuleyman E, Hale C, Saito Y, et al. Vaccine breakthrough infections with SARS-CoV-2 variants. N Engl J Med 2021;384:2212-2218. - PMC - PubMed

Supplementary concepts